HIV Vaccine Awareness Day
Today is HIV Vaccine Awareness Day
HIV Vaccine Awareness Day (HVAD) is observed annually on May 18th. This observance provides an opportunity to recognize and thank the many volunteers, community members, health professionals, and scientists who are working together to find a safe and effective preventive HIV vaccine. It is also a day to educate communities across the nation about the importance of preventive HIV vaccine research.
According to the National Institutes for Health, they have a NIH-funded study which will test safety, efficacy of vaccine regimen through a Large-scale HIV vaccine trial to launch in South Africa.
Also, they note that advances in HIV/AIDS research have given us the opportunity to transform the lives of those living with HIV while providing highly effective methods of preventing the infection. This progress has strengthened optimism for achieving a durable end to the HIV/AIDS pandemic. With an estimated two million new HIV infections occurring worldwide annually, however, controlling and ultimately ensuring a durable end to the HIV/AIDS pandemic also will likely require a safe and effective vaccine.
AVAC has developed a 2016 HVAD “toolkit” (see below) of user-friendly materials to help vaccine advocates explain vaccine science in simple language.
Sustained support from funders, researchers, trial participants, civil society and many other stakeholders is needed to build on important vaccine research lessons learned to date.
HIV Vaccine Awareness Day (HVAD) is observed annually on May 18th. This observance provides an opportunity to recognize and thank the many volunteers, community members, health professionals, and scientists who are working together to find a safe and effective preventive HIV vaccine. It is also a day to educate communities across the nation about the importance of preventive HIV vaccine research.
According to the National Institutes for Health, they have a NIH-funded study which will test safety, efficacy of vaccine regimen through a Large-scale HIV vaccine trial to launch in South Africa.
Also, they note that advances in HIV/AIDS research have given us the opportunity to transform the lives of those living with HIV while providing highly effective methods of preventing the infection. This progress has strengthened optimism for achieving a durable end to the HIV/AIDS pandemic. With an estimated two million new HIV infections occurring worldwide annually, however, controlling and ultimately ensuring a durable end to the HIV/AIDS pandemic also will likely require a safe and effective vaccine.
AVAC has developed a 2016 HVAD “toolkit” (see below) of user-friendly materials to help vaccine advocates explain vaccine science in simple language.
Sustained support from funders, researchers, trial participants, civil society and many other stakeholders is needed to build on important vaccine research lessons learned to date.
HVAD 2016 Advocacy Toolkit: Promising research must continue
- HIV Vaccine Research: An update—A quick, colorful and comprehensive AIDS Vaccine Research Overview. Four pages, five top-line updates. A speedy read designed to give a sense of the moving parts, momentum and major issues coming up in the year to come.
- HIV Vaccines by the Numbers—One-page infographic depicting key numbers of trials, funding, discoveries and more.
- HIV Vaccine Science for Busy Advocates—One-pagers reviewing highlights, next steps and key terms for four pivotal topics:
- HIV Vaccines: The basics—Introductory PowerPoint slide set with basic concepts, an overview of research status and recent developments.
- HIV Vaccines: An introductory fact sheet—Part of AVAC’s basic fact sheet series, a two-pager of basic information and research updates.
- HIV Vaccines: Key messages—Bullet points on today’s pressing issues.